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Background: JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host,
but can be reactivated under immune-compromised conditions potentially causing Progressive Multifocal
Leukoencephalopathy (PML). Detection of antibodies against the major capsid protein VP1 currently is the
main marker for assessment of infection with JCPyV.
Methods: Based on a peptide microarray, peptide JCPyV_VP2_167-15mer was selected and a peptide ELISA
was developed for detection of antibodies directed against this peptide. Epitope mapping and computational
modelling was performed to further characterize this peptide. In a cohort of 204 healthy subjects it was investigated
whether antibodies against JCPyV_VP2_167-15mer were correlated with VP1 serology or urinary viral load.
Results: Epitope mapping of peptide JCPyV_VP2_167-15mer showed that the minimal epitope consisted of
L173PALTSQEI181 with amino acids P174, L176 and E180 being essential for antibody recognition. Computational analysis
was used to predict that this epitope is located at an exposed domain of the VP2 capsid protein, readily accessible for
immune recognition upon infection. No correlation could be observed with JCPyV VP1 antibody levels, or urinary viral
load.
Conclusion: This work indicates that specific antibodies against JCPyV_VP2_167-15mer might be considered as a novel
serological marker for infection with JCPyV.
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JC Polyomavirus (JCPyV) is a human neurotropic poly-
omavirus that was found to be the causative agent of
progressive multifocal leukoencephalopathy (PML), a
fatal demyelinating disease [1-4]. JCPyV can switch from
its latent state to an activated state in immunocom-
promised subjects such as HIV-1 infected patients and
in multiple sclerosis (MS) patients treated with natalizu-
mab [5-7]. The JC Polyomavirus capsid is composed of
72 pentamers of the major capsid protein VP1, with one
of the minor coat proteins (VP2 or VP3) in the center of
each pentamer Both minor proteins are essential for the
viral life cycle [8,9] and were shown to act as membrane* Correspondence: olagatie@its.jnj.com
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membranes [10].
Antibodies to JCPyV VP1 are widely prevalent in
healthy subjects indicating that most individuals have
been exposed to or are latently infected with the virus
[11-17]. Antigenic epitopes have been described for VP1,
with most of these epitopes being shared between JCPyV
and the other polyomaviruses BKPyV and SV40 [18].
Despite this epitope sharing, JCPyV specific serology as-
says using full length recombinant JCPyV VP1 as antigen
were developed. Specificity was shown by inhibition ex-
periments using VP1 from other known polyomaviruses
[19-21]. Serological results should however be inter-
preted with caution as serological cross-reaction with
closely related, yet unidentified human polyomaviruses
can never be excluded [22-24]. Currently, the STRAT-
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and Drug Administration (FDA) approved assay for
JCPyV [12,25].
Little attention has been paid so far to JCPyV VP2 or
VP3 as immunogenic proteins, although some examples
have been described of the immunogenic nature of these
minor capsid proteins in other polyomaviruses. A high
prevalence of antibodies against VP2 has been described
for WU Polyomavirus [26]. Furthermore, a linear epitope
was identified in SV40 VP2/VP3 that showed immuno-
reactivity in serum from 21.9% of blood donors [27].
Also BKPyV VP2 and VP3 were identified as targets of
cellular immunity [28]. Peptide microarray analysis using
a comprehensive set of polyomavirus derived peptides
demonstrated that several non-VP1 peptides were recog-
nized by antibodies in human plasma and could poten-
tially represent linear epitopes of these proteins [29].
In this work we have investigated, using a peptide
microarray setup, whether linear epitopes could be iden-
tified in JCPyV VP2. A 15-mer peptide was identified
that was thereafter used for the development of a pep-
tide ELISA. The immunoreactivity of this peptide was
further characterized and its relationship with other
JCPyV markers was investigated.
Results and discussion
A total of 82 15-mer peptides derived from JCPyV VP2
were incubated in a peptide microarray format with
plasma samples from 49 healthy subjects (HS), resulting
in 4018 data points. All individual data points were plot-
ted per peptide and the mean value and standard devi-
ation was calculated per peptide (Figure 1A). Upon
plotting these descriptive statistics on an x-y plot, 4 pep-
tides clearly had different responses compared to the
other peptides, with high average response and high
variation over the different subjects (Figure 1B). These
peptides were JCPyV_VP2_116-15mer, JCPyV_VP2_167-
15mer (variant with S175 and variant with A175) and
JCPyV_VP2_286-15mer. Remarkably, two variants of the
same peptide (JCPyV_VP2_167-15mer) both had similar
results, suggesting that the variant position is not in-
volved in the epitope recognition. Since JCPyV VP2 is
highly homologous to BKPyV VP2 and SV40 VP2, se-
quence similarity was assessed between the identified
JCPyV peptides and the corresponding peptides in BKPyV
and SV40 (Figure 1C). For peptide JCPyV_VP2_167-
15mer this analysis showed that the corresponding SV40
peptide overlaps largely with a peptide that was identified
earlier as an epitope that is recognized by antibodies in
serum samples from healthy donors carrying SV40 [27].
As there is also low sequence homology of this peptide
with the corresponding BKPyV and SV40 peptides, we de-
cided to further investigate this specific JCPyV peptide. In
order to verify that human plasma samples contain IgGantibodies that react with this specific peptide, a pep-
tide ELISA was set up using the synthetic peptides
JCPyV_VP2_167-15mer and BKPyV_VP2_167-15mer.
This ELISA was used to test for anti-peptide antibody
responses in plasma from 50 HSs that had been diluted
200-fold (Figure 1D). This confirmed that plasma from
healthy individuals indeed contains IgG antibodies
reacting with this peptide, with an overall prevalence
of 64% (32/50) for JCPyV_VP2_167-15mer and only
14% (7/50) for BKPyV_VP2_167-15mer.
Molecular modelling was performed on a 36-mer, cov-
ering amino acids 154 to 189 of JCPyV VP2 (Figure 2).
This modelling predicts that this peptide is characterized
by a stable secondary structure consisting of 2 α helix
domains flanking a smaller exposed amino acid stretch.
This computational modelling indicates that the majority
of JCPyV_VP2_167 is located in an exposed region of
the VP2 protein and as such this physical configuration
might favour its immunological reactivity, in line with
the results observed in the peptide ELISA.
In order to better characterize the immunoreactivity of
this JCPyV VP2 derived peptide, epitope mapping exper-
iments were performed. For this investigation, a peptide
ELISA was employed to test 3 plasma samples that were
highly reactive towards JCPyV_VP2_167-15mer using
different specifically designed synthetic peptides. On the
one hand a series of 7-mers, 9-mers, 11-mers and 13-
mers, overlapping with all but one residue was tested
(Figure 3A). This test showed that a minimal peptide re-
quired to retain immunoreactivity consisted of the se-
quence LPALTSQEI. This observation was confirmed by
the analysis of anti-peptide antibody responses in plasma
from 50 HSs using the 9-mer, 11-mer, 13-mer and
15-mer that was found to retain immunoreactivity
(Figure 3B). On the other hand each of the amino acids
in JCPyV_VP2_167-15mer was replaced individually by
alanine (alanine walking) (Figure 3C). Using this ap-
proach the contribution of each specific residue used to
the immunoreactivity of the peptide is determined
[30,31]. The data obtained using these peptides in the pep-
tide ELISA indicate that three residues in JCPyV_VP2_167-
15mer are important for antibody recognition: P174, L176
and E180. Replacement of any of these residues by alanine
resulted in the complete elimination of immunoreactivity
of the peptide. These data also confirmed the results of the
previous experiment as all essential amino acid residues are
located within the minimal peptide affirmed. Remark that
the corresponding BKPyV peptide (IPSITSQEL) has an iso-
leucine residue at position 176 instead of leucine.
Since several mutations have been described in the
VP2 region of JCPyV, it might be of interest to investi-
gate whether some of these mutations are located in the
JCPyV_VP2_167-15mer. A first mutation that is known,
is the E172 mutation [32]. However, this residue is not
Figure 1 Identification of JCPyV_VP2_167-15mer as immunoreactive peptide. (A) Distribution of the JCPyV VP2 polyomavirus 15-mer
peptide microarray signals obtained with plasma samples from 49 HSs, diluted at 1:200. Peptides with the largest signal distribution are indicated
in red (JCPyV_VP2_116-15mer), green (JCPyV_VP2_167-15mer, light green is S175 variant, dark green is A175 variant) and blue (JCPyV_VP2_286-15mer).
(B) Average signal in microarray vs. standard deviation of signal over the different subjects, plotted per peptide. (C) Similarity between peptides
specific to JCPyV, BKPyV and SV40 for the 3 selected JCPyV peptides. (D) Plasma antibody reactivity of 50 HSs against JCPyV_VP2_167-15mer and
BKPyV_VP2_167-15mer, with data presented as log2 (signal of test sample / signal of the no-sample control). Samples were diluted at 1:200 and
detected in a peptide ELISA.
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play a role in antibody recognition. A second mutation
is the S175 mutation which was already part of our initial
investigation on the peptide array. Based on both the
array data and the epitope mapping data, it is clear that
this residue also does not play a role in antibody recog-
nition. Taken together, we might conclude that thepeptide ELISA using the JCPyV_VP2_167-15mer
NLVRDDLPALTSQEI is capable of detecting anti-
bodies against all JCPyV strains, independent of the
strain specific sequence of this VP2 region.
The data presented above are demonstrative of the im-
munoreactivity of JCPyV_VP2_167-15mer and its minimal
epitope LPALTSQEI. This does however not imply that
Figure 2 Secondary structure visualization (PEP-FOLD) of the
results of the computational analysis carried out on synthetic
polypeptide JCPyV_VP2_154_36-mer.
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to or infection with JCPyV. Any protein containing the
LPALTSQEI sequence or closely related sequence
might in fact be the antigen responsible for the positive
immune responses observed. The responses observed
with JCPyV_VP2_167-15mer would then be non-
specific responses. In order to investigate the possibil-
ity that a protein from another organism might be at
the basis of the observed responses, a protein BLAST
search was performed against the non-redundant pro-
tein database using JCPyV_VP2_171-11mer as query
sequence [33] (Additional file 1: Table S1). Within the
Viridae only SA12 VP2 and BKPyV VP2 were identi-
fied, respectively with 1 or 4 mismatches compared to
the query sequence. Also in the human proteome no
proteins were identified with less than 4 mismatches.
Most proteins with less than 4 mismatches compared
to JCPyV_VP2_171-11mer, however, were found in
Bacteria and Animalia. Also one protein from protozoan
origin and one protein from a grass species were identi-
fied. Of all identified sequences the corresponding 15-mer
peptide was synthesized and used for assessment of their
immunoreactivity in 3 plasma samples that were highly re-
active towards JCPyV_VP2_167-15mer. Out of the 30 pep-
tides tested, 9 showed some response in the peptideELISA that were similar as JCPyV_VP2_167-15mer
(Figure 4). The strongest signals were observed for iso-
propylmalate isomerase from Micrococcus luteus,
anti-FecI sigma factor FecR from Spirosoma linguale
DSM 74, hypothetical protein from Beggiatoa alba,
putative perixosomal biogenesis factor from Ixodes
scapularis and probable E3 ubiquitin-protein ligase
ARI1-like from Brachypodium distachyon. Although it
cannot be excluded, it is very unlikely that one of these
proteins is responsible for the immune response
observed in the peptide ELISA using JCPyV_VP2_167-
15mer. First of all some of these organisms are either
rare or occur only at specific locations. Secondly, the
proteins identified are not expected to be strong anti-
gens as they are known to be located intracellularly
and as such are unlikely to be exposed to the host’s
humoral immune system. All together, these data sug-
gest that an immune response against JCPyV VP2 can
be observed in HSs and that the amino acid stretch
with sequence LPALTSQEI functions as an epitope on
this protein.
Based on these data, we believe JCPyV_VP2_167-
15mer truly acts as an epitope and therefore the peptide
ELISA using JCPyV_VP2_167-15mer as antigen was
employed to analyse the immune response against this
peptide in a larger cohort of 204 HSs (Figure 5). As was
already seen in the smaller cohort of 50 HSs, there was a
large variation over the different subjects. Subjects were
further categorized based on their JCPyV VP1 serology
and JCPyV urinary viral load (Figure 5A). However, no
difference (P > 0.05) between JCPyV VP1 seropositive
and seronegative subjects could be observed. The same
was observed when comparing subjects shedding virus
in their urine and virus with a negative urinary viral
load. Although we have shown before there is no cross-
reactivity with BKPyV, we investigated the possibility
that infection with BKPyV was interfering in the assay.
Therefore, also BKPyV VP1 antibody levels were deter-
mined and subjects were categorized based on their
JCPyV VP1 and BKPyV VP1 serology (Figure 5B). Again,
no difference (P > 0.05) was observed between any of the
groups. It is known urinary viral load and JCPyV VP1
antibody levels are correlated [34]. We have investigated
whether this is also true for JCPyV_VP2_167 antibody
levels (Figure 5C). In contrast to VP1 antibody levels, no
correlation was found between urinary viral load and
JCPyV_VP2_167 antibodies (P > 0.05). It was also appar-
ent that JCPyV_VP2_167 antibody levels were not corre-
lated with donor age (P > 0.05, Figure 5D). It will also be
of interest for future studies to investigate whether
JCPyV_VP2_167 antibody levels remain constant over
time as is the case for VP1 antibody levels [35,36].
The lack of correlation between JCPyV_VP2_167 and
JCPyV VP1 antibody levels is an interesting, but surprising
Figure 3 Epitope mapping of JCPyV_VP2_167-15mer. (A) Analysis of 7-mers, 9-mers, 11-mers and 13-mers. Plasma antibody reactivity of plasma
samples from 3 HSs (diluted 1:200) with high immunoreactivity against the wild type peptide was determined. (B) Plasma antibody reactivity of 50 HSs
against JCPyV_VP2_173-9mer, JCPyV_VP2_171-11mer, JCPyV_VP2_169-13mer and JCPyV_VP2_167-15mer. Samples were diluted at 1:200 and detected
in a peptide ELISA. (C) Alanine walking of JCPyV_VP2_167-15mer. Plasma antibody reactivity of plasma samples from 3 HSs (diluted 1:200) with high
immunoreactivity against the wild type peptide was determined.
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serology is debated for its use as the sole infection
marker as several examples have been described where
JCPyV DNA was detected in urine, plasma or specific
blood cell populations of individuals who wereseronegative for JCPyV VP1 [37-40]. In recent work,
also a lack of correlation was observed between the
level of anti-JCPyV antibody and anti-JCPyV neutraliz-
ing activity as 28.6% of JCPyV VP1 Ab+ samples were
not capable of neutralizing the in vitro infection of
Figure 4 Plasma antibody reactivity of plasma samples from 3 HSs (diluted 1:200) with high immunoreactivity against JCPyV_VP2_167-
15mer was determined using peptides derived from BLAST analysis of JCPyV_VP2_167-15mer (Additional file 1: Table S1).
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ever be needed to investigate whether JCPyV_VP2_167
antibodies are capable of neutralizing JCPyV infection.
It might be debated whether JCPyV VP2 can be recog-
nized by the immune system as it was proposed that
VP2 is located at the inner side of the capsid [42]. Crystal
structure analysis however showed that the N-terminal part
of VP2, including the JCPyV_VP2_167-15mer region is not
tightly folded and retains high flexibility, making it easier
for VP2 to emerge from inside the virion [43,44]. The fact
that it was also shown that 52.3% of serum samples show
immunoreactivity with WU Polyomavirus VP2 and 21.9%
of blood donors react with SV40 VP2 derived peptides,
strengthens the conclusion that JCPyV VP2 acts as an anti-
gen recognized by the immune system upon JCPyV infec-
tion [26,27]. We postulate that the peptide studied in this
work, JCPyV_VP2_167-15mer, acts as one of the epitopes
responsible for the antigenic properties of JCPyV VP2.
Conclusions
The work presented here shows that plasma from a large
portion of HSs reacts specifically with a peptide derived
from JCPyV VP2 capsid protein. Epitope mapping experi-
ments demonstrated that the minimal epitope consisted of
L173PALTSQEI181 with amino acids P174, L176 and E180 es-
sential for antibody recognition. Computational analysis
was used to show that this epitope is located at an exposed
domain of the VP2 capsid protein, readily accessible for
immune recognition upon infection. Furthermore, thispeptide is also located in a region homologous to an im-
munoreactive domain in SV40 VP2 [27]. BLAST analysis
of this peptide and subsequent experimental analysis of
the obtained peptides showed that a number of alternative
proteins might exist that could have elicited the observed
immune responses. However, based on the limited geo-
graphical distribution of some of the organisms encoding
these proteins and the intracellular localization of most of
these proteins, it is unlikely that this would be the case, in-
dicating that the immune responses should have been in-
duced by infection with or exposure to JCPyV. The fact
that there appears to be no correlation with JCPyV VP1
antibody levels, nor urinary viral load, indicates that these
specific antibodies might be considered as a novel marker
for infection with JCPyV.
Material and methods
Ethics statement
The Ethics Committee [“Commissie voor Medische
Ethiek - ZiekenhuisNetwerk Antwerpen (ZNA) and the
Ethics committee University Hospital Antwerp] ap-
proved the Protocols, and Informed consents, which
were signed by all subjects.
Healthy subject samples
For the screening study a total of 50 healthy subjects
were recruited in Belgium, for the evaluation study a
total of 204 healthy subjects (HS) were recruited in
Belgium [14,29,45]. The demographic description of the
Figure 5 Plasma antibody reactivity of 204 HSs against JCPyV_VP2_167-15mer. (A) Subjects were grouped based on JCPyV VP1 serostatus
(VP1 Ab- and VP1 Ab+) and on urinary viral load (VL- and VL+) and antibody reactivity against JCPyV_VP2_167-15mer was determined in the different
groups. (B) Subjects were grouped based on JCPyV VP1 serostatus and BKPyV VP1 serostatus (JCV-BKV-, JCV-BKV+, JCV+BKV- and JCV+BKV+)
and antibody reactivity against JCPyV_VP2_167-15mer was determined in the different groups. (C) Correlation analysis of plasma antibody
reactivity against JCPyV_VP2_167-15mer and JCPyV urinary viral load in HSs. (D) Correlation analysis of plasma antibody reactivity against
JCPyV_VP2_167-15mer and age.
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and urine samples were collected from all these HS and
stored at −80°C until further processing.JC polyomavirus viral load assay
Analysis of the urinary viral load was performed as de-
scribed previously [14].JC polyomavirus VP1 serology assay
The anti-JCPyV antibody assay was performed as de-
scribed earlier [45]. Samples were considered positive if
OD values were higher than 2-fold the OD value of the
blank sample (i.e. log2 test/ctrl > 1).BK polyomavirus VP1 serology assay
The anti-JCPyV antibody assay was performed identi-
cal to the method described for JCPyV VP1 with the
exception that microtiter plates were coated with
baculovirus expressed BKPyV VP1 capsid protein
(Eurogentec, Belgium). Samples were considered posi-
tive if OD values were higher than 2-fold the OD value
of the blank sample (i.e. log2 test/ctrl > 1).JC polyomavirus VP2 peptide microarrays
Peptide microarrays were performed as part of the work
that was described earlier [29]. For this study only the
peptides from JCPyV VP2 were included for further de-
tailed analysis.
Table 1 Overview of subjects investigated
Variable Screening study (n = 50) Evaluation study (n = 204)
Gender, n (%)
Male 22 (44%) 97 (48%)
Female 28 (56%) 107 (52%)
Age, median (Min-Max) 40.5 (23–59) 42 (19–66)
Race, ethnicity, n (%)
White 38 (76%) 201 (98.5%)
Black 3 (6%) 0 (0%)
Asian 8 (16%) 2 (1%)
Other/unknown 1 (2%) 1 (0.5%)
JCPyV VP1 serology, n (%)
Positive 36 (72%) 156 (57%)
Negative 14 (28%) 88 (43%)
JCPyV Viruria, n (%)
Positive* 13 (26%) 50 (25%)
Negative 37 (74%) 154 (75%)
BKPyV VP1 serology, n (%)
Positive n.d. 178 (88%)
Negative n.d. 24 (12%)
JCPyV_VP2_167-15mer serology, n (%)
Positive 32 (64%) 165 (81%)
Negative 18 (36%) 39 (19%)
*All JCPyV viruric subjects were part of the JCPyV VP1 seropositive subgroup.
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Molecular modeling was carried out using the program
PEP-FOLD (web server http://mobyle.rpbs.univ-paris-di-
derot.fr/cgi-bin/portal.py#forms::PEP-FOLD, [46,47]). The
peptide sequence of JCPyV_VP2_154_36-mer (GPSLFSTI
SQAFWNLVRDDLPALTSQEIQRRTQK) was submitted
to the server for peptide folding and resulting structure
was visualized using Jmol.
Synthetic peptides
Biotinylated synthetic peptides were synthesized by
standard procedures and purchased from JPT Innovative
Peptide Solutions (Berlin, Germany Peptide serology
assay). A list of all peptide sequences used in this study
is provided in Additional file 2: Table S2.
Peptide serology assays
For determination of peptide specific plasma antibody
levels peptide ELISA was developed and set up as fol-
lows. Ninety-six well flat bottom plates (Nunc C96
Maxisorp, VWR) were coated with 100 μL of 1 μg/mL
Streptavidin from Streptomyces avidinii (Sigma) in Dulbecco’s
PBS without calcium and magnesium (Gibco). The
plates were incubated at 4°C for 16 hours. The plates were
rinsed once with 200 μL PBS + 0.05% Tween-20 (washingbuffer) and blocked for 1 hour at 37°C with 200 μL of 10-
fold diluted Blocker Casein (Pierce) in PBS (blocking solu-
tion). Upon removal of the blocking solution, plates were
incubated with continuous shaking for 2 hours at room
temperature with 100 μL of the selected biotinylated pep-
tide, which were diluted at 1 μg/mL in blocking solution.
The plates were rinsed 3 times with washing buffer,
thereby eliminating unbound peptide. Then, the different
wells were covered with 100 μL of human plasma samples,
diluted 1:200 in blocking solution. Each sample was ana-
lyzed in duplicate. In control wells, blocking solution was
added instead. The plate was incubated at 37°C for 1 hour.
After incubation, a new triple rinsing cycle was repeated
as described above. Then, the secondary antibody solution
was added to each well. The solution contained an affinity
purified Donkey anti-human IgG (H + L) peroxidase con-
jugate (Jackson ImmunoResearch) diluted 1:10,000 in
blocking solution. The reaction mixture was incubated at
37°C for 1 hour. At the end of the incubation period, the
plates were rinsed 3 times with washing buffer and treated
with 100 μL SureBlue™ TMB Microwell Peroxidase Sub-
strate (KPL). After 10 minutes of incubation the colori-
metric reaction was stopped with 100 μL 1 N HCl. The
plate was then read by the spectrophotometer (Spectra-
Max, Molecular Devices) at a wavelength (λ) of 450 nm.
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higher than 2-fold the OD value of the blank sample (i.e.
log2 test/ctrl > 1).
Statistical analysis
Differences in antibody levels between groups were
assessed using a Mann-Whitney test. Differences between
groups were considered statistically significant at P < 0.05.
Correlation between different parameters was analyzed
using linear regression. P-value was calculated to determine
whether slope was significantly non-zero and strength of
correlation was determined using r-value. All statistical ana-
lyses were performed using GraphPad Prism v 5.04.
Additional files
Additional file 1: Table S1. Proteins identified upon BLAST analysis of
JCV_VP2_171-11mer.
Additional file 2: Table S2. Sequences of peptides used in this study.
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